Annual Report

The report records FY2017 consolidated net sales of ¥101,448 million and describes growth in its pharmaceutical and functional-food businesses. It highlights Gazyva's July 2018 approval and a drug pipeline focused on hematology, urology, and rare and intractable diseases. The report also presents environmental performance against the company's energy, CO2 emissions-intensity, landfill-waste, and recycling targets.

Report type

Annual Report with Sustainability Disclosures

Class

Embedded

Scope

Full report

Fiscal year

2017-2018

Period

1 April 2017 – 31 March 2018

Language

English

Pages

 

File size

 

GRI

••••••

SASB

••••••

TCFD

••••••

ISSB

••••••

ESRS

••••••

Integrated Reporting Framework

••••••

GHG Protocol

••••••

EU Taxonomy

••••••

CDP

••••••

Other

••••••

Assessment

••••••

Basis

••••••

Statement included

••••••